



1600

ENTERED

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/851,422B

DATE: 09/11/2002
TIME: 10:41:23

Input Set : A:\EP.txt
Output Set: N:\CRF4\09112002\I851422B.raw

3 <110> APPLICANT: Bajaj, Paul
5 <120> TITLE OF INVENTION: Region of Factor IXa Protease Domain that Interacts with
Factor VIIIa and
6 Methods Therefor
8 <130> FILE REFERENCE: 66153-9628
C--> 10 <140> CURRENT APPLICATION NUMBER: US/09/851,422B
C--> 11 <141> CURRENT FILING DATE: 2002-08-21
13 <160> NUMBER OF SEQ ID NOS: 8
15 <170> SOFTWARE: PatentIn version 3.1
17 <210> SEQ ID NO: 1
18 <211> LENGTH: 9
19 <212> TYPE: PRT
20 <213> ORGANISM: Homo sapiens
22 <400> SEQUENCE: 1
24 Leu Val Asp Arg Ala Thr Cys Leu Arg
25 1 5
28 <210> SEQ ID NO: 2
29 <211> LENGTH: 4
30 <212> TYPE: PRT
31 <213> ORGANISM: Homo sapiens
33 <400> SEQUENCE: 2
35 Asp Arg Ala Thr
36 1
39 <210> SEQ ID NO: 3
40 <211> LENGTH: 5
41 <212> TYPE: PRT
42 <213> ORGANISM: Homo sapiens
44 <400> SEQUENCE: 3
46 Ala Asp Arg Ala Thr
47 1 5
50 <210> SEQ ID NO: 4
51 <211> LENGTH: 5
52 <212> TYPE: PRT
53 <213> ORGANISM: Homo sapiens
55 <400> SEQUENCE: 4
57 Asp Arg Ala Thr Ala
58 1 5
61 <210> SEQ ID NO: 5
62 <211> LENGTH: 7
63 <212> TYPE: PRT
64 <213> ORGANISM: Homo sapiens
66 <400> SEQUENCE: 5
68 Arg Leu Met Thr Gln Asp Gln
69 1 5

RECEIVED
SEP 20 2002
TECH CENTER 1600/2900

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/851,422B

DATE: 09/11/2002
TIME: 10:41:23

Input Set : A:\EP.txt
Output Set: N:\CRF4\09112002\I851422B.raw

72 <210> SEQ ID NO: 6
73 <211> LENGTH: 5
74 <212> TYPE: PRT
75 <213> ORGANISM: Homo sapiens
77 <400> SEQUENCE: 6
79 Tyr Asn Ser Lys Leu
80 1 5
83 <210> SEQ ID NO: 7
84 <211> LENGTH: 6
85 <212> TYPE: PRT
86 <213> ORGANISM: Homo sapiens
88 <400> SEQUENCE: 7
90 Ile Glu Pro Val Lys Asp
91 1 5
94 <210> SEQ ID NO: 8
95 <211> LENGTH: 7
96 <212> TYPE: PRT
97 <213> ORGANISM: Homo sapiens
99 <400> SEQUENCE: 8
101 Val Pro His Asn Glu Ser Glu
102 1 5

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/851,422B

DATE: 09/11/2002
TIME: 10:41:24

Input Set : A:\EP.txt
Output Set: N:\CRF4\09112002\I851422B.raw

Invalid Line Length:
The rules require that a line not exceed 72 characters in length. This includes spaces.

Seq#:1; Line(s) 5

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/851,422B

DATE: 09/11/2002

TIME: 10:41:24

Input Set : A:\EP.txt

Output Set: N:\CRF4\09112002\I851422B.raw

L:10 M:270 C: Current Application Number differs, Replaced Current Application Number
L:11 M:271 C: Current Filing Date differs, Replaced Current Filing Date

1642



1600

ENTERED

P#16

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/851,422A

DATE: 09/11/2002
TIME: 10:30:35

Input Set : A:\35879122.app
Output Set: N:\CRF4\09112002\I851422A.raw

3 <110> APPLICANT: YU, XIANXHANG
 4 WAGNER, THOMAS E.
 6 <120> TITLE OF INVENTION: THERAPEUTIC PORE-FORMING PEPTIDES
 8 <130> FILE REFERENCE: 035879/0122
 10 <140> CURRENT APPLICATION NUMBER: 09/851,422A
 11 <141> CURRENT FILING DATE: 2001-05-09
 13 <150> PRIOR APPLICATION NUMBER: 60/203,063
 14 <151> PRIOR FILING DATE: 2000-05-09
 16 <150> PRIOR APPLICATION NUMBER: 60/212,042
 17 <151> PRIOR FILING DATE: 2000-06-16
 19 <160> NUMBER OF SEQ ID NOS: 12
 21 <170> SOFTWARE: PatentIn Ver. 2.1
 23 <210> SEQ ID NO: 1
 24 <211> LENGTH: 37
 25 <212> TYPE: PRT
 26 <213> ORGANISM: Artificial Sequence
 28 <220> FEATURE:
 29 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 30 peptide
 32 <220> FEATURE:
 33 <221> NAME/KEY: MOD_RES
 34 <222> LOCATION: (10)..(13)
 35 <223> OTHER INFORMATION: This region may be selected from the group consisting of
 [epsilon]
 36 -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
 37 -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
 38 -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
 40 <220> FEATURE:
 41 <221> NAME/KEY: MOD_RES
 42 <222> LOCATION: (22)..(25)
 43 <223> OTHER INFORMATION: This region may be selected from the group consisting of
 [epsilon]
 44 -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
 45 -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
 46 -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
 48 <220> FEATURE:
 49 <221> NAME/KEY: MOD_RES
 50 <222> LOCATION: (34)..(37)
 51 <223> OTHER INFORMATION: This region may be selected from the group consisting of
 [epsilon]
 52 -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
 53 -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
 54 -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
 56 <220> FEATURE:

RECEIVED
 SEP 20 2002
 TECH CENTER 1600/2900

57 <223> OTHER INFORMATION: This molecule may encompass smaller embodiments according
58 to the application as filed

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/851,422A

DATE: 09/11/2002
TIME: 10:30:35

Input Set : A:\35879122.app
Output Set: N:\CRF4\09112002\I851422A.raw

60 <400> SEQUENCE: 1
W--> 61 Gly Phe Ile Ala Thr Leu Cys Thr Lys Xaa Xaa Xaa Xaa Val Leu Asp
62 1 5 10 15
W--> 64 Phe Gly Ile Asp Lys Xaa Xaa Xaa Xaa Leu Ile Gln Leu Ile Glu Asp
65 20 25 30
W--> 67 Lys Xaa Xaa Xaa Xaa
68 35
71 <210> SEQ ID NO: 2
72 <211> LENGTH: 38
73 <212> TYPE: PRT
74 <213> ORGANISM: Artificial Sequence
76 <220> FEATURE:
77 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
78 peptide
80 <220> FEATURE:
81 <221> NAME/KEY: MOD_RES
82 <222> LOCATION: (8)..(11)
83 <223> OTHER INFORMATION: This region may be selected from the group consisting of
[epsilon]
84 -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
85 -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
86 -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
88 <220> FEATURE:
89 <221> NAME/KEY: MOD_RES
90 <222> LOCATION: (26)..(29)
91 <223> OTHER INFORMATION: This region may be selected from the group consisting of
[epsilon]
92 -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
93 -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
94 -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
96 <220> FEATURE:
97 <221> NAME/KEY: MOD_RES
98 <222> LOCATION: (32)..(35)
99 <223> OTHER INFORMATION: This region may be selected from the group consisting of
[epsilon]
100 -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
101 -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
102 -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
104 <220> FEATURE:
105 <223> OTHER INFORMATION: This molecule may encompass smaller embodiments according
106 to the application as filed
108 <400> SEQUENCE: 2
W--> 109 Gly Ile Gly Ala Val Leu Lys Xaa Xaa Xaa Xaa Val Leu Thr Thr Gly
110 1 5 10 15
W--> 112 Leu Pro Ala Leu Ile Ser Trp Ile Lys Xaa Xaa Xaa Xaa Arg Lys Xaa
113 20 25 30
W--> 115 Xaa Xaa Xaa Arg Gln Gln
116 35
119 <210> SEQ ID NO: 3
120 <211> LENGTH: 25
121 <212> TYPE: PRT
122 <213> ORGANISM: Entamoeba histolytica

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/851,422A

DATE: 09/11/2002
TIME: 10:30:35

Input Set : A:\35879122.app
Output Set: N:\CRF4\09112002\I851422A.raw

124 <400> SEQUENCE: 3
125 Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp
126 1 5 10 15
128 Lys Leu Ile Gln Leu Ile Glu Asp Lys
129 20 25
132 <210> SEQ ID NO: 4
133 <211> LENGTH: 37
134 <212> TYPE: PRT
135 <213> ORGANISM: Antheraea pernyi
137 <220> FEATURE:
138 <223> OTHER INFORMATION: Cecropin A
140 <400> SEQUENCE: 4
141 Lys Trp Lys Leu Phe Lys Lys Ile Glu Lys Val Gly Gln Asn Ile Arg
142 1 5 10 15
144 Asp Gly Ile Ile Lys Ala Gly Pro Ala Val Ala Val Val Gly Gln Ala
145 20 25 30
147 Thr Gln Ile Ala Lys
148 35
151 <210> SEQ ID NO: 5
152 <211> LENGTH: 35
153 <212> TYPE: PRT
154 <213> ORGANISM: Antheraea pernyi
156 <220> FEATURE:
157 <223> OTHER INFORMATION: Cecropin B
160 <400> SEQUENCE: 5
161 Lys Trp Lys Ile Phe Lys Lys Ile Glu Lys Val Gly Arg Asn Ile Arg
162 1 5 10 15
164 Asn Gly Ile Ile Lys Ala Gly Pro Ala Val Ala Val Leu Gly Glu Ala
165 20 25 30
167 Lys Ala Leu
168 35
171 <210> SEQ ID NO: 6
172 <211> LENGTH: 36
173 <212> TYPE: PRT
174 <213> ORGANISM: Antheraea pernyi
176 <220> FEATURE:
177 <223> OTHER INFORMATION: Cecropin D
179 <400> SEQUENCE: 6
180 Trp Asn Pro Phe Lys Glu Leu Glu Lys Val Gly Gln Arg Val Arg Asp
181 1 5 10 15
183 Ala Val Ile Ser Ala Gly Pro Ala Val Ala Thr Val Ala Gln Ala Thr
184 20 25 30
186 Ala Leu Ala Lys
187 35
190 <210> SEQ ID NO: 7
191 <211> LENGTH: 26
192 <212> TYPE: PRT
193 <213> ORGANISM: Apis mellifera
195 <400> SEQUENCE: 7

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/851,422A

DATE: 09/11/2002
TIME: 10:30:35

Input Set : A:\35879122.app
Output Set: N:\CRF4\09112002\I851422A.raw

196 Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
197 1 5 10 15
199 Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln
200 20 25
203 <210> SEQ ID NO: 8
204 <211> LENGTH: 27
205 <212> TYPE: PRT
206 <213> ORGANISM: Artificial Sequence
208 <220> FEATURE:
209 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
210 peptide
212 <220> FEATURE:
213 <221> NAME/KEY: MOD_RES
214 <222> LOCATION: (26)..(27)
215 <223> OTHER INFORMATION: [epsilon-gamma]-Glu-[alpha-gamma]-Glu
217 <400> SEQUENCE: 8
218 Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp
219 1 5 10 15
W--> 221 Lys Leu Ile Gln Leu Ile Glu Asp Lys Xaa Xaa
222 20 25
225 <210> SEQ ID NO: 9
226 <211> LENGTH: 26
227 <212> TYPE: PRT
228 <213> ORGANISM: Artificial Sequence
230 <220> FEATURE:
231 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
232 peptide
234 <220> FEATURE:
235 <221> NAME/KEY: MOD_RES
236 <222> LOCATION: (26)
237 <223> OTHER INFORMATION: [epsilon-alpha]-Phe
239 <400> SEQUENCE: 9
240 Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp
241 1 5 10 15
W--> 243 Lys Leu Ile Gln Leu Ile Glu Asp Lys Xaa
244 20 25
247 <210> SEQ ID NO: 10
248 <211> LENGTH: 27
249 <212> TYPE: PRT
250 <213> ORGANISM: Artificial Sequence
252 <220> FEATURE:
253 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
254 peptide
256 <220> FEATURE:
257 <221> NAME/KEY: MOD_RES
258 <222> LOCATION: (18)
259 <223> OTHER INFORMATION: [epsilon-alpha]-Phe
261 <220> FEATURE:
262 <221> NAME/KEY: MOD_RES

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/851,422A

DATE: 09/11/2002

TIME: 10:30:35

Input Set : A:\35879122.app
 Output Set: N:\CRF4\09112002\I851422A.raw

```

263 <222> LOCATION: (27)
264 <223> OTHER INFORMATION: [epsilon-alpha]-Phe
266 <400> SEQUENCE: 10
267 Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp
268   1           5           10          15
W--> 270 Lys Xaa Leu Ile Gln Leu Ile Glu Asp Lys Xaa
271           20          25
274 <210> SEQ ID NO: 11
275 <211> LENGTH: 28
276 <212> TYPE: PRT
277 <213> ORGANISM: Artificial Sequence
279 <220> FEATURE:
280 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
281     peptide
283 <220> FEATURE:
284 <221> NAME/KEY: MOD_RES
285 <222> LOCATION: (22)
286 <223> OTHER INFORMATION: [epsilon-gamma]-Glu
288 <220> FEATURE:
289 <221> NAME/KEY: MOD_RES
290 <222> LOCATION: (25)
291 <223> OTHER INFORMATION: [epsilon-gamma]-Glu
293 <400> SEQUENCE: 11
294 Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
295   1           5           10          15
W--> 297 Ile Ser Trp Ile Lys Xaa Arg Lys Xaa Arg Gln Gln
298           20          25
301 <210> SEQ ID NO: 12
302 <211> LENGTH: 30
303 <212> TYPE: PRT
304 <213> ORGANISM: Artificial Sequence
306 <220> FEATURE:
307 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
308     peptide
310 <220> FEATURE:
311 <221> NAME/KEY: MOD_RES
312 <222> LOCATION: (22)..(23)
313 <223> OTHER INFORMATION: [epsilon-gamma]-Glu-[alpha-gamma]-Glu
315 <220> FEATURE:
316 <221> NAME/KEY: MOD_RES
317 <222> LOCATION: (26)..(27)
318 <223> OTHER INFORMATION: [epsilon-gamma]-Glu-[alpha-gamma]-Glu
320 <400> SEQUENCE: 12
321 Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
322   1           5           10          15
W--> 324 Ile Ser Trp Ile Lys Xaa Xaa Arg Lys Xaa Xaa Arg Gln Gln
325           20          25          30

```

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/851,422A

DATE: 09/11/2002
TIME: 10:30:36

Input Set : A:\35879122.app
Output Set: N:\CRF4\09112002\I851422A.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 10,11,12,13,22,23,24,25,34,35,36,37
Seq#:2; Xaa Pos. 8,9,10,11,26,27,28,29,32,33,34,35
Seq#:8; Xaa Pos. 26,27
Seq#:9; Xaa Pos. 26
Seq#:10; Xaa Pos. 18,27
Seq#:11; Xaa Pos. 22,25
Seq#:12; Xaa Pos. 22,23,26,27

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/851,422A

DATE: 09/11/2002
TIME: 10:30:36

Input Set : A:\35879122.app
Output Set: N:\CRF4\09112002\I851422A.raw

L:61 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0
L:64 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:16
L:67 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:32
L:109 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:0
L:112 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:16
L:115 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:32
L:221 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8 after pos.:16
L:243 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9 after pos.:16
L:270 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10 after pos.:16
L:297 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11 after pos.:16
L:324 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12 after pos.:16